English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduPennsylvania legislators and top medical experts will come together to address the growing xylazine crisis at an upcoming free symposium. The event, titled “The Next Chapter of the Opioid Epidemic in Pennsylvania: The Xylazine Crisis,” will be held on November 23, 2024, at the Bluemle Life Science Building at Jefferson Med in Philadelphia.
Tag: xylazine
Rothman Orthopaedic Institute Foundation to Host Symposium on Xylazine Crisis in Pennsylvania
The Rothman Orthopaedic Institute Foundation for Opioid Research & Education announces a symposium titled “The Next Chapter of the Opioid Epidemic in Pennsylvania: The Xylazine Crisis” to be held on November 23, 2024, from 8:30 am to 12:30 pm at the Bluemle Life Science Building at Jefferson Med in Philadelphia.
Scientists Discover Surprising Details about Xylazine in Combination with Fentanyl
Xylazine, often found in street-drug combo with fentanyl, was thought to only bind to the α2-adrenergic receptor, but UNC-Chapel Hill scientists discovered it also binds to opioid receptors, which could have profound impacts on fentanyl overdose treatment.
Researchers describe horrific effects of new drug threat, xylazine, or “tranq”
Xylazine, an animal sedative that is approved by the U.S. Food and Drug Administration (FDA) for veterinary use only, has made its way into the illicitly manufactured fentanyl (IMF) supply and has significantly increased in prevalence in recent years, likely due to its low cost, easy availability, and presumed enhanced “high.” Researchers reviewed pertinent xylazine research and pulled from their own clinical experience to offer new guidance on the care of patients exposed to this dangerous drug. Their review is published in Annals of Internal Medicine.